Interpret the DEXA and FRAX results for a 62‑year‑old female (lumbar spine T‑score +1.6, left femoral‑neck T‑score –0.6, left total‑hip T‑score +0.5, 10‑year major osteoporotic fracture risk 6%, hip fracture risk 0.2%) and advise on management.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bone Density Interpretation: Normal Bone Health with No Treatment Indicated

This 62-year-old female has excellent bone density across all measured sites and does not require pharmacological treatment for osteoporosis. Her FRAX scores indicate low fracture risk, and she falls well below all treatment thresholds established by major guidelines.

DEXA Results Analysis

T-Score Interpretation

All three measured sites demonstrate normal bone mineral density according to WHO criteria 1:

  • Lumbar spine (L1-L4): T-score +1.6 (significantly above normal threshold of ≥-1.0)
  • Left femoral neck: T-score -0.6 (normal range)
  • Left total hip: T-score +0.5 (above normal threshold)

The lowest T-score among all sites is -0.6 at the femoral neck, which is the value used for diagnostic classification 2, 1. This places her firmly in the normal bone density category, nowhere near the osteoporosis threshold of ≤-2.5 or even the osteopenia range of -1.0 to -2.5.

Z-Score Context

Her Z-scores are notably elevated (lumbar spine Z-score +3.0, femoral neck +0.7, total hip +1.5), indicating her bone density is at or above her age-matched peers 1. The markedly elevated lumbar spine Z-score (3 standard deviations above age-matched mean) warrants consideration of potential artifacts from degenerative changes, but this does not affect her overall normal classification since her hip measurements are definitively normal.

FRAX Risk Assessment

Her 10-year fracture probabilities are well below treatment thresholds 2, 3, 4:

  • Major osteoporotic fracture risk: 6.0% (treatment threshold: ≥20%)
  • Hip fracture risk: 0.2% (treatment threshold: ≥3%)

These values place her at low fracture risk and do not meet criteria for pharmacological intervention according to AACE/ACE, NOF, and Endocrine Society guidelines 2, 3, 4.

Management Recommendations

No Pharmacological Treatment Required

Pharmacological therapy is NOT indicated because she fails to meet any of the established treatment criteria 2, 4:

  1. ❌ No T-score ≤-2.5 at any site
  2. ❌ No history of fragility fracture mentioned
  3. ❌ FRAX major osteoporotic fracture risk <20% (hers is 6.0%)
  4. ❌ FRAX hip fracture risk <3% (hers is 0.2%)

Lifestyle and Preventive Measures

Implement these evidence-based non-pharmacological interventions 2, 5, 4:

Calcium and Vitamin D Supplementation:

  • Calcium: 1,200 mg daily (dietary plus supplementation)
  • Vitamin D: 600-800 IU daily
  • Target serum vitamin D level: ≥20 ng/mL (50 nmol/L) 5

Exercise Program:

  • Weight-bearing exercises (walking, jogging, dancing)
  • Resistance training for muscle strengthening
  • Balance exercises to reduce fall risk 2, 4

Lifestyle Modifications:

  • Smoking cessation if applicable
  • Limit alcohol to ≤2 units per day
  • Maintain healthy body weight 2, 4

Fall Prevention:

  • Home safety assessment (remove tripping hazards, improve lighting)
  • Vision and hearing checks
  • Review medications that may increase fall risk 2

Follow-Up DEXA Timing

Repeat DEXA in 3-5 years or longer interval given her excellent baseline bone density 2, 6. More frequent monitoring (1-2 years) is reserved for patients on treatment or with documented bone loss. Her normal bone density and low fracture risk do not warrant aggressive surveillance.

Earlier repeat DEXA only if:

  • New fragility fracture occurs
  • Initiation of medications causing bone loss (e.g., glucocorticoids >3 months, aromatase inhibitors)
  • Development of conditions associated with secondary osteoporosis (hyperparathyroidism, malabsorption, chronic kidney disease)
  • Significant unintentional weight loss

Important Clinical Caveats

Lumbar Spine Artifact Consideration

The unusually high lumbar spine T-score (+1.6) and Z-score (+3.0) may reflect degenerative changes (facet joint osteoarthritis, osteophytes, aortic calcification) that artificially elevate BMD measurements 1. However, this does not change management since:

  • Hip measurements are the most reliable for fracture prediction in older adults
  • Her hip T-scores are definitively normal
  • Diagnosis is based on the lowest T-score, which is at the femoral neck (-0.6)

FRAX Limitations

While FRAX is widely used, recognize its limitations 7:

  • Does not incorporate lumbar spine BMD
  • Uses binary inputs for glucocorticoids and alcohol (yes/no rather than dose)
  • May underestimate risk in patients with multiple vertebral fractures, recent fractures, or certain secondary causes
  • Race-specific calculations may affect treatment thresholds

In this patient, FRAX appropriately identifies low risk, and these limitations do not apply.

When to Reassess

Immediately reassess if she experiences:

  • Any low-trauma fracture (hip, spine, wrist, humerus, pelvis)
  • Height loss >2 cm or new back pain suggesting vertebral fracture
  • Initiation of high-risk medications

Summary Statement

This patient has normal bone density with low fracture risk and requires only lifestyle modifications and routine monitoring. Pharmacological treatment would provide no benefit and expose her to unnecessary medication risks and costs. Focus counseling on calcium/vitamin D adequacy, regular weight-bearing exercise, fall prevention, and smoking cessation if applicable. Reassure her that her bone health is excellent for her age, and schedule follow-up DEXA in 3-5 years or sooner if clinical circumstances change 2, 4.

References

Guideline

acr appropriateness criteria® osteoporosis and bone mineral density: 2022 update.

Journal of the American College of Radiology, 2022

Guideline

american association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update <i>executive summary</i>.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2020

Guideline

american association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2020

Guideline

acog releases practice bulletin on osteoporosis.

American family physician, 2013

Guideline

updated practice guideline for dual-energy x-ray absorptiometry (dxa).

European Journal of Nuclear Medicine and Molecular Imaging, 2025

Related Questions

Can you interpret the DXA results and advise management for a 70‑year‑old patient with lumbar spine T‑score –0.6 (normal), left femoral neck T‑score –1.4 (osteopenia), left total‑hip T‑score –0.1 (normal), and FRAX 10‑year major osteoporotic fracture risk 4.4% and hip fracture risk 0.5%?
Can you interpret the bone density results for a 71‑year‑old patient, including lumbar spine, left femoral‑neck, and left total‑hip T‑scores and the FRAX 10‑year fracture risk estimates?
How should a dual‑energy X‑ray absorptiometry (DEXA) scan be interpreted and when is zoledronic acid indicated?
Can you explain in layperson terms my ten-year major osteoporotic fracture risk (11%) and hip fracture risk (1.5%) given osteopenia of the left proximal femur, normal lumbar spine, and decreasing bone mineral density?
In a patient with osteoporosis who has been on anti‑resorptive therapy for three years and now has a dual‑energy X‑ray absorptiometry (DXA) T‑score of –1.2, what is the appropriate next step in management?
How should I evaluate and manage a non‑diabetic adult with asymptomatic stage 1 acute kidney injury (possible stage 2 if oliguria), severe hypertension, complement‑mediated thrombotic microangiopathy, normal glucose, normal diet, and moderate‑large ketonuria, who is at home and not hospitalized?
How should I manage a stable patient who experienced an allergic reaction with bilateral lower‑extremity edema and urticaria one week ago?
What are the side effects of the pentazocine‑atropine‑promethazine cocktail when used in an adult undergoing a brief upper‑airway or oral‑cavity procedure?
In an asymptomatic non‑diabetic adult with acute kidney injury and suspected complement‑mediated thrombotic microangiopathy who reports large carbohydrate‑rich meals, what is the significance of ketonuria and does it require specific treatment?
What is the appropriate management of an adverse reaction—including respiratory depression, anticholinergic toxicity, extrapyramidal symptoms, hypotension, or promethazine extravasation—in a patient receiving a pentazocine‑atropine‑promethazine combination?
Is foul-smelling stool associated with severe liver disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.